A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
Phase 3
Completed
NCT04673786
| Condition | Psoriasis |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Celltrion |
|---|
| Status | Completed |
|---|
| Enrollment | 509 participants |
|---|
| Interventions | CT-P43, Stelara |
|---|
| Start date | Jan 11, 2021 |
|---|
| Completion date | Aug 4, 2021 |
|---|
| Results posted | Jun 5, 2023 |
|---|
Summary
This study is a randomized, active-controlled, double-blind, phase 3 study to compare the efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque psoriasis.
The Mean Percent Improvement From Baseline in PASI Score at Week 12
From baseline to Week 12 · percentage of improvement in PASI score
| CT-P43 | 77.93 ± 1.771 percentage of improvement in PASI score |
|---|
| EU-Stelara | 75.89 ± 1.739 percentage of improvement in PASI score |
|---|
| Treatment difference (%) and 90% CI | 2.05 (95% CI -0.23–4.32) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.